Hartford Investment Management Co. Sells 877 Shares of Eli Lilly and Company $LLY

Hartford Investment Management Co. cut its stake in Eli Lilly and Company (NYSE:LLY) by 1.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 46,582 shares of the company’s stock after selling 877 shares during the period. Eli Lilly and Company makes up 1.1% of Hartford Investment Management Co.’s holdings, making the stock its 12th largest position. Hartford Investment Management Co.’s holdings in Eli Lilly and Company were worth $35,542,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dash Acquisitions Inc. boosted its position in Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after acquiring an additional 13 shares during the last quarter. Nvest Financial LLC raised its holdings in shares of Eli Lilly and Company by 0.6% in the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock valued at $1,773,000 after purchasing an additional 13 shares during the last quarter. MPS Loria Financial Planners LLC lifted its position in shares of Eli Lilly and Company by 1.9% in the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock worth $545,000 after purchasing an additional 13 shares in the last quarter. Key Client Fiduciary Advisors LLC boosted its holdings in Eli Lilly and Company by 1.2% during the third quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock worth $867,000 after purchasing an additional 13 shares during the last quarter. Finally, Darwin Wealth Management LLC grew its position in Eli Lilly and Company by 3.6% in the third quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock valued at $285,000 after purchasing an additional 13 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Deutsche Bank Aktiengesellschaft boosted their price target on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Four research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,162.75.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Announced U.S. manufacturing expansion to support higher-volume production and speed delivery for breakthrough therapies — improves supply resilience for Mounjaro/Zepbound and future launches. Eli Lilly and Company (LLY) expands US manufacturing and advances breakthrough therapies
• Positive Sentiment: Ventyx Biosciences set a March 3 vote on a $14/share cash merger with Lilly — an acquisition could add early‑stage assets and talent to Lilly’s oncology/rare disease pipeline, with potential near-term dilution but longer-term portfolio upside. Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger
• Positive Sentiment: Entered a strategic collaboration with Repertoire Immune Medicines to broaden immuno‑oncology and discovery capabilities — partnership accelerates access to novel modalities and external innovation. Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines
• Positive Sentiment: Analyst upgrade and a higher price target were published this week — supports near‑term sentiment and valuation narratives. Eli Lilly and Company (NYSE:LLY) Shares Up 1.3% Following Analyst Upgrade
• Neutral Sentiment: Coverage previews and analyst notes ahead of Q4 earnings highlight GLP‑1 demand (Mounjaro, Zepbound) but flag watch items — earnings will be the immediate catalyst for guidance and margin commentary. What’s in Store for These 5 Pharma Bigwigs This Earnings Season?
• Neutral Sentiment: Pre‑earnings analyst piece weighs buy/hold/sell arguments: strong GLP‑1 sales versus emerging oral competition and pricing risk — positions vary by investor time horizon. Should Investors Buy, Sell or Hold Lilly Stock Ahead of Q4 Earnings?
• Positive Sentiment: Analysis on using GLP‑1 platform strength to build a broader pipeline — indicates management is leveraging core capabilities to diversify revenue streams beyond obesity/diabetes. Eli Lilly Uses GLP 1 Strength To Build Broader Drug Pipeline
• Negative Sentiment: Reuters reports U.S. GLP‑1 prices are falling amid intensifying competition and cash‑pay entrants — this could compress near‑term revenue growth and margin expectations for Lilly and peers. Obesity market sales potential tightens as Novo and Lilly enter new era

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,043.87 on Tuesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The business’s 50 day moving average price is $1,056.39 and its two-hundred day moving average price is $892.18. The company has a market cap of $986.86 billion, a PE ratio of 51.07, a price-to-earnings-growth ratio of 0.78 and a beta of 0.39. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.